{
    "clinical_study": {
        "@rank": "21762", 
        "arm_group": {
            "arm_group_label": "RoActemra/Actemra", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, single-arm study will evaluate the safety and efficacy of RoActemra/Actemra\n      alone or concomitant with other antirheumatic drugs when administered as a single, weekly\n      injection in patients with rheumatoid arthritis."
        }, 
        "brief_title": "A Study of the Efficacy and Safety of RoActemra/Actemra in Patients With Rheumatoid Arthritis.", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients >/= 18 years of age\n\n          -  Patients with a diagnosis of active RA according to the revised (1987) ACR criteria\n             on EULAR/ACR (2010) criteria\n\n          -  Patients who were previously treated with:\n\n          -  Three non-biologic DMARDs, and were not treated with any biologic agent; OR\n\n          -  One biologic agent (alone or in combination with non-biologic DMARDs), and\n             discontinued that agent for a reason\n\n          -  Oral corticosteroids (</= 10 mg/day prednisone or equivalent), NSAIDs and\n             non-biologic DMARDs are permitted if on a stable dose regimen for >/= 4 weeks prior\n             to Baseline\n\n          -  Use of effective contraception throughout the study as defined by protocol; female\n             patients of childbearing potential must not be pregnant\n\n        Exclusion Criteria:\n\n          -  Presence of serious, uncontrolled, clinically significant medical conditions\n\n          -  History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic\n             ulcerative lower GI disease that might predispose to perforation\n\n          -  Current or history of recurrent bacterial, viral, fungal, mycobacterial, or other\n             infections\n\n          -  Any infection requiring hospitalization or treatment with IV antibiotics within 4\n             weeks of Screening or oral antibiotics within 2 weeks of Screening\n\n          -  Clinically significant findings on lab tests and/or hepatitis B or C, or HIV\n             screenings\n\n          -  Active TB requiring treatments within the previous 3 years\n\n          -  Evidence of active malignant disease, malignancies diagnosed within the previous 10\n             years, or breast cancer diagnosed within the previous 20 years\n\n          -  History of alcohol, drug, or chemical abuse within 1 year prior to Screening\n\n          -  Neuropathies or other conditions that might interfere with pain evaluation\n\n          -  Major surgery (including joint surgery) within 8 weeks prior to Screening or planned\n             major surgery within 6 months following Baseline\n\n          -  Rheumatic autoimmune disease other than RA, including systemic lupus erythematosus,\n             mixed connective tissue disorder, scleroderma, polymyositis, or significant systemic\n             involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty's\n             syndrome). Secondary Sj\u00f6gren's syndrome with RA is permitted\n\n          -  Functional Class IV as defined by the ACR Classification of Functional Status\n             in-Rheumatoid Arthritis (Appendix 2)\n\n          -  Diagnosis of juvenile idiopathic arthritis or juvenile RA, and/or RA before the age\n             of 16\n\n          -  Prior history of current inflammatory joint disease other than RA\n\n          -  Exposure to RoActemra/Actemra (either IV or SC) at any time prior to Baseline\n\n          -  Treatment with any investigational agent within 4 weeks (or five half-lives of the\n             investigational drug, whichever is longer) of Screening\n\n          -  Previous treatment with any cell-depleting therapies, including investigational\n             agents approved therapies, with alkylating agents such as chlorambucil, or with total\n             lymphoid irradiation\n\n          -  Treatment with IV gamma globulin, plasmapheresis within 6 months of Baseline\n\n          -  Immunization with a live/attenuated vaccine within 4 weeks prior to Baseline"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01988012", 
            "org_study_id": "ML28698"
        }, 
        "intervention": {
            "arm_group_label": "RoActemra/Actemra", 
            "description": "162 mg administered subcutaneously once a week", 
            "intervention_name": "tocilizumab [RoActemra/Actemra!", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beer Sheva", 
                        "country": "Israel", 
                        "zip": "8410101"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beer Yaacov", 
                        "country": "Israel", 
                        "zip": "6093000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel", 
                        "zip": "34354"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel", 
                        "zip": "34362"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel", 
                        "zip": "3339419"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jerusalem", 
                        "country": "Israel", 
                        "zip": "9112001"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jerusalem", 
                        "country": "Israel", 
                        "zip": "91240"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kfar Saba", 
                        "country": "Israel", 
                        "zip": "44281"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Petach Tikva", 
                        "country": "Israel", 
                        "zip": "4941492"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Petach Tikva", 
                        "country": "Israel", 
                        "zip": "49372"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ramat Gan", 
                        "country": "Israel", 
                        "zip": "5262000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ramat Gan", 
                        "country": "Israel", 
                        "zip": "52620-00"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tel Aviv", 
                        "country": "Israel", 
                        "zip": "6423906"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Multicenter Study to Evaluate Disease Activity and Safety of Treatment With Actemra (Tocilizumab) Administered as Subcutaneous Injection in Adult RA Patients.", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28698 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Efficacy: Patient-reported outcome of disease activity", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Efficacy: Change in disease activity, scored on CDAI/SDAI", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 24"
            }, 
            {
                "measure": "Efficacy: Proportion of patients in remission/with lowered disease score", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Efficacy: Reduction/discontinuation of parallel therapies.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01988012"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Patient-reported quality of life assessment", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "32 weeks"
            }, 
            {
                "measure": "Safety: Assessment of immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "32 weeks"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}